ArticleCellular oncology (Dordrecht, Netherlands)2015
KLF15 in breast cancer: a novel tumor suppressor?
Article in Cellular oncology (Dordrecht, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 70 citations in OpenAlex.
- A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer.BMC cancer · 2023Trial
- KLF15 activates PGC1α to rewire mitochondrial homeostasis and overcome cisplatin resistance in lung adenocarcinoma.Cell death discovery · 2026Article
- KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability.Cellular and molecular life sciences : CMLS · 2024Article
- Article
- KLF15 transcriptionally activates LINC00689 to inhibit colorectal cancer development.Communications biology · 2024Article
- Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants.Cancer research · 2023Article
- Comprehensive research into prognostic and immune signatures of transcription factor family in breast cancer.BMC medical genomics · 2023Article
- Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer.Translational andrology and urology · 2023Article
- KLF15 suppresses tumor growth and metastasis in Triple-Negative Breast Cancer by downregulating CCL2 and CCL7.Scientific reports · 2022Article
- Article
- The functions and prognostic value of Krüppel-like factors in breast cancer.Cancer cell international · 2022Article
- MiR-181a promotes cell proliferation and migration through targeting KLF15 in papillary thyroid cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Expression and Prognosis Value of the KLF Family Members in Colorectal Cancer.Journal of oncology · 2022Article
- Protein Ligands in the Secretome of CD36Cancers · 2021Article
- Depletion of Kruppel-like factor 15 sensitized gliomas to temozolomide cytotoxicity throughBiochemistry and biophysics reports · 2021Article
- Krüppel-Like Factor 15 ModulatesFrontiers in cell and developmental biology · 2021Article
- Localized and Systemic Inflammatory Mediators in a Murine Acute Mastitis Model.Journal of inflammation research · 2021Article
- EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.Nucleic acids research · 2020Article
- LncRNA LUCAT1/miR-181a-5p axis promotes proliferation and invasion of breast cancer via targeting KLF6 and KLF15.BMC molecular and cell biology · 2020Article
- The Importance of Breast Adipose Tissue in Breast Cancer.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKrüppel-like factor 15 (KLF15) is a transcription factor that is involved in various biological processes, including cellular proliferation, differentiation and death. In addition, KLF15 has recently been implicated in the development of several human malignancies, including breast cancer. In vitro breast cancer studies have pointed at a putative role in the regulation of cell proliferation. As yet, however, KLF15 expression analyses in primary human breast cancers have not been reported. Here, we set out to investigate the clinical and biological significance of KLF15 expression in human breast cancers.
methodsKLF15 expression was evaluated by immunohistochemistry in 54 primary invasive ductal breast carcinomas, and its status was correlated with various clinicopathological parameters. We also assessed KLF15 expression in vitro in 4 breast cancer-derived cell lines using Western blotting, and examined the effects of exogenous KLF15 expression on cell cycle progression using flow cytometry. Concomitant (changes in) p21, p27 and TOPO2A expression levels were examined using real-time RT-PCR and immunocytochemistry, respectively.
resultsIn ~90% of the primary breast carcinoma tissues tested, KLF15 was found to be expressed and localized in either the cytoplasm, the nucleus or both. Predominant nuclear immunoreactivity was found to be associated with clinicopathological factors predicting a better clinical outcome (i.e., ER positive, HER2 negative, low grade, low Ki-67 expression). The breast cancer-derived cell lines tested showed a low KLF15 expression with a predominant cytoplasmic localization. Subsequent exogenous KLF15 over-expression resulted in a predominant nuclear localization and a concomitant decreased cellular proliferation and an arrest at the G0/G1 phase of the cell cycle. In addition, we found that nuclear KLF15 expression results in up-regulation of p21, a pivotal suppressor of the G1 to S phase transition of the cell cycle.
conclusionsOur results indicate that nuclear KLF15 expression suppresses breast cancer cell proliferation at least partially through p21 up-regulation and subsequent cell cycle arrest. This is a first study addressing the role of KLF15 in breast cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.